RJA
APLS

Raymond James & Associates’s Apellis Pharmaceuticals APLS Stock Holding History

Raymond James & Associates’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.38M Buy
48,010
+18,428
+62% +$682K ﹤0.01% 2471
2024
Q2 		$1.13M Buy
29,582
+10,627
+56% +$481K ﹤0.01% 2542
2024
Q1 		$1.11M Buy
18,955
+3,568
+23% +$227K ﹤0.01% 2528
2023
Q4 		$921K Sell
15,387
-26,633
-63% -$1.35M ﹤0.01% 2562
2023
Q3 		$1.6M Sell
42,020
-3,530
-8% -$155K ﹤0.01% 2150
2023
Q2 		$4.15M Sell
45,550
-15,978
-26% -$1.38M ﹤0.01% 1606
2023
Q1 		$4.06M Buy
61,528
+47,091
+326% +$2.72M ﹤0.01% 1606
2022
Q4 		$747K Buy
14,437
+405
+3% +$21.5K ﹤0.01% 2608
2022
Q3 		$958K Buy
14,032
+5,983
+74% +$354K ﹤0.01% 2422
2022
Q2 		$364K Buy
8,049
+1,664
+26% +$75.9K ﹤0.01% 3107
2022
Q1 		$324K Sell
6,385
-455
-7% -$20.1K ﹤0.01% 3366
2021
Q4 		$323K Sell
6,840
-416
-6% -$16.4K ﹤0.01% 3387
2021
Q3 		$239K Sell
7,256
-264
-4% -$14.8K ﹤0.01% 3569
2021
Q2 		$475K Sell
7,520
-7,998
-52% -$413K ﹤0.01% 3112
2021
Q1 		$666K Buy
15,518
+9,340
+151% +$442K ﹤0.01% 2798
2020
Q4 		$353K Buy
+6,178
New +$261K ﹤0.01% 3027
2020
Q3 		– Sell
-6,422
Closed -$210K – 3589
2020
Q2 		$210K Sell
6,422
-1,753
-21% -$56.3K ﹤0.01% 3098
2020
Q1 		$219K Buy
+8,175
New +$290K ﹤0.01% 2976

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Raymond James & Associates's APLS Position: Q3 2024 in Review

Raymond James & Associates increased its Apellis Pharmaceuticals (APLS) stake by 62% in Q3 2024, buying an estimated $682K and bringing the position to 48,010 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2471.

Raymond James & Associates first reported a position in APLS in Q1 2020 and has held it in 18 quarters since. The position peaked at $4.15M in Q2 2023. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • Raymond James & Associates held 48,010 shares of Apellis Pharmaceuticals worth $1.38M as of Q3 2024.
  • Raymond James & Associates bought 18,428 Apellis Pharmaceuticals shares in Q3 2024, an estimated $682K.
  • Apellis Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2471 holding.
  • Raymond James & Associates first reported a position in Apellis Pharmaceuticals in Q1 2020 and has held it in 18 quarters since.
  • Raymond James & Associates's Apellis Pharmaceuticals position peaked at $4.15M in Q2 2023.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.